ELEBER 60mg concentrate+solvent for solution for infusion medication leaflet

L01CD04 cabazitaxel • Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Taxanes

Cabazitaxelum is a medication used for the treatment of metastatic castration-resistant prostate cancer, particularly in patients previously treated with docetaxel. It is a chemotherapeutic agent from the taxane class that interferes with microtubule function, inhibiting cell division and causing cancer cell death.

The medication is administered via intravenous infusion, usually once every three weeks, in combination with prednisone, as directed by a doctor. The treatment requires close monitoring to manage side effects and assess the patient's response.

Common side effects include fatigue, nausea, diarrhea, decreased blood cell counts, and hair loss. In rare cases, severe adverse effects such as febrile neutropenia or allergic reactions may occur.

Cabazitaxelum is not recommended for pregnant or breastfeeding women. Patients should inform their doctor about all medications they are taking to avoid drug interactions.

General data about ELEBER 60mg

Substance: cabazitaxel

Date of last drug list: 10-04-2026

Commercial code: W67781001

Concentration: 60mg

Pharmaceutical form: concentrate+solvent for solution for infusion

Quantity: 1

Product type: generic

Price: 11692.81 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PHARMADOX HEALTHCARE LTD. - MALTA

Holder: ZENTIVA K.S. - REPUBLICA CEHA

Number: 13967/2021/01

Shelf life: 3 years

Concentrations available for cabazitaxel

10mg/ml, 20mg/ml, 60mg

Other substances similar to cabazitaxel

Compensation lists for ELEBER 60mg ZENTIVA

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

11692.81 RON

9551.03 RON

2141.78 RON